(Q33927990)

30 July 2017

title

Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer (English)

1 reference

30 July 2017

1 reference

1 reference

13

Ravi Salgia

1 reference

30 July 2017

14

Mark J Ratain

1 reference

30 July 2017

1

Federico Innocenti

1 reference

30 July 2017

Richard L Schilsky

2

1 reference

30 July 2017

Jacqueline Ramírez

3

1 reference

30 July 2017

Linda Janisch

4

1 reference

30 July 2017

Samir Undevia

5

1 reference

30 July 2017

Larry K House

6

1 reference

30 July 2017

Soma Das

7

1 reference

30 July 2017

Kehua Wu

8

1 reference

30 July 2017

Michelle Turcich

9

1 reference

30 July 2017

Robert Marsh

10

1 reference

30 July 2017

Theodore Karrison

11

1 reference

30 July 2017

Michael L Maitland

12

1 reference

30 July 2017

language of work or name

English

0 references

publication date

23 June 2014

1 reference

Journal of Clinical Oncology

30 July 2017

published in

1 reference

30 July 2017

volume

32

1 reference

30 July 2017

issue

22

1 reference

30 July 2017

page(s)

2328-2334

1 reference

Clinical implementation of germ line cancer pharmacogenetic variants during the next-generation sequencing era.

30 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4105486

The Cancer Genome Atlas Pan-Cancer analysis project

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4105486

Designing transformative clinical trials in the cancer genome era.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4105486

A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4105486

Expansion of cancer care and control in countries of low and middle income: a call to action

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4105486

Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4105486

RECIST revisited: a review of validation studies on tumour assessment

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4105486

Systemic therapy for colorectal cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4105486

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4105486

Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4105486

Impact of body-size measures on irinotecan clearance: alternative dosing recommendations

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4105486

High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4105486

Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4105486

Translating the cancer genome into clinically useful tools and strategies

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4105486

Characterization of the UDP glucuronosyltransferase activity of human liver microsomes genotyped for the UGT1A1*28 polymorphism

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4105486

UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4105486

Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4105486

Horseshoes, hand grenades, and body-surface area-based dosing: aiming for a target

29 October 2018

1 reference

12 December 2020

Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism

1 reference

12 December 2020

Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin

1 reference

12 December 2020

The Role of UGT1A1*28 Polymorphism in the Pharmacodynamics and Pharmacokinetics of Irinotecan in Patients With Metastatic Colorectal Cancer

1 reference

12 December 2020

Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping

1 reference

12 December 2020

The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity

1 reference

12 December 2020

Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28

1 reference

12 December 2020

UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters

1 reference

12 December 2020

Hepatocyte nuclear factor-1 alpha is associated with UGT1A1, UGT1A9 and UGT2B7 mRNA expression in human liver

1 reference

12 December 2020

Task force hopes to deliver affordable cancer drugs to developing countries

1 reference

12 December 2020

Identifiers

DOI

10.1200/JCO.2014.55.2307

1 reference

release_pm7cby6ujnecpeivywt2zxjtga

30 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/pm7cby6ujnecpeivywt2zxjtga

24 November 2022

mapped directly with Wikidata item

PMC publication ID

4105486

1 reference

30 July 2017

1 reference